Today, the Chairman & CEO of Veracyte (VCYT), Bonnie Anderson, sold shares of VCYT for $183.9K.
Following Bonnie Anderson’s last VCYT Sell transaction on November 09, 2017, the stock climbed by 17.1%. This is Anderson’s first Sell trade following 3 Buy transactions.
See today’s analyst top recommended stocks >>
Based on Veracyte’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $29.53 million and GAAP net loss of $1.92 million. In comparison, last year the company earned revenue of $20.04 million and had a GAAP net loss of $9.18 million. Currently, Veracyte has an average volume of 502.8K. The Company has a Price to Book ratio of 11.7187.
The insider sentiment on Veracyte has been negative according to 35 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Veracyte, Inc. engages in the research, development, and commercialization of diagnostic products. Its portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis.
